This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Book Profits on Medical Stocks

Last 12-Month Return (%): Stocks with a red number declined by that percentage over the last 12 months. Stocks with a black number increased by that percentage.

Forecast 1-Year Return: Stocks with a red number are projected to decline by that percentage over the next 12 months. Stocks with a black number in the table are projected to move higher by that percentage over the next 12 months.

Value Level: The price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.

Pivot: A level between a value level and risky level that should be a magnet during the timeframe noted.

Risky Level: The price at which to enter a GTC Limit Order to sell on strength.

Abbott Labs (ABT - Get Report) ($69.35 vs. $68.29 on Aug. 8) set an all time high at $69.60 on Sept. 19. ABT has been rated a buy according to ValuEngine, has a reasonable P/E ratio and is well above its 200-day SMA at $60.78. Reduce your long position then look to buy weakness to my quarterly value level at $64.20.

Amgen (AMGN - Get Report) ($81.71 vs. $81.57 on Aug. 8) set a multiyear high at $85.27 on Aug. 27. AMGN remains buy rated, has a reasonable P/E ratio and is well above its 200-day SMA at $71.30. Employ a "buy and trade" strategy between the value level and risky level.

Bristol Myers (BMY - Get Report) ($32.90 vs. $32.54 on Aug. 8) set a multiyear high at $36.34 on July 2. BMY remains buy rated, has a reasonable P/E ratio and is below its 200-day SMA at $33.50. Employ a "buy and trade" strategy between the value level and risky level.

Express Scripts (ESRX - Get Report) ($62.98 vs. $56.02 on Aug. 8) set an all-time high at 64.33 on Sept. 6. ESRX remains buy rated, has so-so P/E ratio and is well above its 200-day SMA at $54.14. Employ a "buy and trade" strategy between the value level and risky level.

Gilead Sciences (GILD) ($67.21 vs. 57.552 on Aug. 8) set an all-time high at $67.55 on Sept. 18. GILD has been downgraded to hold from buy Thursday morning, has an elevated P/E ratio and is well above its 200-day SMA at $49.92. Reduce your long position then look to buy weakness to my quarterly value level at $51.69.

Johnson & Johnson (JNJ) ($68.60 vs $68.29 on Aug. 8) set a multiyear high at $69.75 on Aug. 1. JNJ remains buy rated, has a reasonable P/E ratio and is well above its 200-day SMA at $65.69. Sell strength to my quarterly pivot at $69.81 then employ a "buy and trade" strategy between the value level and risky level.

Eli Lilly (LLY) ($46.86 vs. $42.75 on August 8) set a multiyear high at $47.26 on Sept. 13. LLY remains buy rate, has a reasonable P/E ratio and is well above its 200-day SMA at $41.37. Reduce your long position then look to buy weakness to my quarterly value level at $44.03.

Merck (MRK) ($44.51 vs. $44.00 on Aug. 8) set a multiyear high at $45.17 on July 27. MRK remains buy rated, has a favorable P/E ratio and is well above its 200-day SMA at $39.66. Reduce your long position then look to buy weakness to my quarterly value level at $39.13.

Pfizer (PFE) ($24.16 vs. $23.74 on August 8) set a multiyear high at $24.48 on July 31. PFE remains buy rated, has a favorable P/E ratio and is well above its 200-day SMA at $22.38. Employ a "buy and trade" strategy between the value level and risky level.

United Health Group (UNH) ($54.95 vs. $52.54 on August 8) - set a multi-year high at $60.75 on June 19. UNH remains Strong Buy rated, has a favorable P/E ratio and is just above its 200-day SMA at $54.56. Employ a "buy and trade" strategy between the value level and risky level.

Nine of the stocks profiled today are overvalued fundamentally with UNH undervalued by 12.2%. Seven of ten have overbought weekly chart profiles. BMY and JNJ have declining momentum. UNH has rising momentum as the stock becomes a Dow Component. All ten have traded higher by 11.0% (JNJ) to 67.8% (GILD) over the past twelve months, have P/E ratios between 10.7 (PFE) and 19.8 (GILD). In my judgment when these stocks turn lower the stocks above their 200-day simple moving averages have risk to this key support.



At the time of publication the author held no positions in any of the stocks mentioned.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

Richard Suttmeier has an engineering degree from Georgia Tech and a master of science from Brooklyn Poly. He began his career in the financial services industry in 1972 trading U.S. Treasury securities in the primary dealer community. In 1981 he formed the Government Bond Department at LF Rothschild and helped establish that firm as a primary dealer in 1986. Richard began writing market research in 1984 and held positions as market strategist at firms such as Smith Barney, William R Hough, Joseph Stevens, and Rightside Advisors. He joined www.ValuEngine.com in 2008 producing newsletters covering the U.S. capital markets, and a universe of more than 7,000 stocks. Richard employs a "buy and trade" investment strategy and can be reached at RSuttmeier@Gmail.com.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
XLV $75.13 0.07%
ABT $49.27 0.53%
AMGN $157.27 -2.00%
BMY $69.16 1.10%
ESRX $89.23 -0.56%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs